佐力药业(300181) - 2025 Q1 - 季度业绩预告

Financial Performance - The estimated net profit attributable to shareholders for Q1 2025 is projected to be between RMB 178 million and RMB 189 million, representing a year-on-year growth of 24.99% to 32.71% compared to RMB 142.42 million in the same period last year[2]. - The estimated net profit after deducting non-recurring gains and losses is expected to be between RMB 177.8 million and RMB 189.8 million, reflecting a growth of 23.79% to 32.14% from RMB 143.63 million in the previous year[2]. - The company anticipates a net profit of RMB 185 million to RMB 196 million after accounting for a reduction of approximately RMB 7 million in net profit due to share-based payment expenses related to the 2024 restricted stock incentive plan[2][5]. - Non-recurring gains and losses are expected to impact net profit by an amount ranging from RMB -800,000 to RMB 200,000[5]. - The financial data in this earnings forecast has not been audited by an accounting firm[3]. - The specific financial data will be detailed in the company's Q1 2025 report[6]. Product Growth - The growth is attributed to the market expansion of three core products: Wuling Capsules, Bailing Tablets, and Lingze Tablets, which are included in the national essential drug list[4]. - The company has seen continuous growth in traditional Chinese medicine formula granules as the number of registered varieties increases year-on-year[4].